Cognition Therapeutics Inc (CGTX) — Institutional Holders Breakdown (Q2 2026)

CGTX ranks #5468 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

CGTX is a top-conviction position for BIOS Capital Management, LP — at 16.6% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

CM Management, LLC has added to its CGTX position for two straight quarters, increasing it by $247.5K to reach $517.5K today.

Jim Simons has trimmed its CGTX position for two straight quarters, cutting it by $511.6K while still holding $797.3K.

CGTX is up 4% today, and institutions have been net buyers of $2.3M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

CGTX reported a net loss of $23.5M in its latest fiscal year.

• Not yet profitable — net loss of $23.5M in the latest fiscal year
• Net income improved year over year, from -$34.0M to -$23.5M
• Operating cash flow was negative, using $24.6M in cash
• Current ratio of 3.45x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.41x equity — within a conventional range